DSDerek G. Southwell

Derek G. Southwell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Derek G. Southwell has a total of 255 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Shared latent representations of speech production for cross-patient speech decoding

    by Z. Spalding, S. Duraivel, S. Rahimpour, C. Wang, K. Barth, C. Schmitz, S. P. Lad, A. H. Friedman, D. G. Southwell, J. Viventi, et al.

    Speech brain-computer interfaces (BCIs) can restore communication in individuals with neuromotor disorders who are unable to speak. However, current speech BCIs limit patient usability and successful deployment by requiring large volumes of patient-specific data collected over long periods of time. A promising solution to facilitate usability and accelerate their successful deployment is to combine data from multiple patients. This has proven difficult, however, due to differences in user neuroanatomy, varied placement of electrode arrays, and sparse sampling of targeted anatomy. Here, by aligning patient-specific neural data to a shared latent space, we show that speech BCIs can be trained on data combined across patients. Using canonical correlation analysis and high-density micro-electrocorticography (μECoG), we uncovered shared neural latent dynamics with preserved micro-scale speech information. This approach enabled cross-patient decoding models to achieve improved performance relative to patient-specific models facilitated by the high resolution and broad coverage of μECoG. Our findings support future speech BCIs that are more accurate and rapidly deployable, ultimately improving the quality of life for people with impaired communication from neuromotor disorders.

  • Open Access

    Thalamo-cortical synchrony shapes seizure expression in human temporal lobe epilepsy

    by Thandar Aung, Jian Li, Tipakorn Tumnark, Chandana Belly, John Thomas, Kassem Jaber, Prachi Parikh, Muhammad Zafar, Derek Southwell, Patrick Chauvel, et al.

    In drug-resistant temporal lobe epilepsy (DR-TLE), some seizures are clinically symptomatic while others remain electrographic despite arising from the same seizure-onset zone (SOZ), suggesting that clinical expression reflects network dynamics beyond seizure origin. We examined whether thalamo-cortical network engagement differs between clinical (CS) and non-clinical seizures (NCS). We analyzed 286 seizures from 62 DR-TLE patients recorded using stereoelectroencephalography with pulvinar and/or anterior thalamic group coverage. Thalamo-cortical synchrony during the first 20 seconds of seizure onset was quantified as correlation between SEEG-derived time-frequency patterns in thalamic nuclei and the cortical SOZ. Synchrony was significantly stronger during CS than NCS (p < 0.0001, Cliff's δ > 0.6), including within-subject analyses, and was independent of other clinical variables, including postsurgical outcome. Linear mixed-effects modeling identified seizure type as the sole independent predictor of synchrony (p = 0.0069). These findings identify thalamo–cortical synchrony as a network-level feature associated with clinical seizure expression in DR-TLE.


  • Intraoperative Laryngeal Muscle and Heart Rate Responses to Implanted Vagus Nerve Stimulation

    by Kathryn M. Turk, Kevin J. Mohsenian, Jennifer J. Peters, Derek G. Southwell, Warren M. Grill, Nicole A. Pelot


  • Open Access

    Viral Microglia Reprogramming Clears Oligomeric Neurotoxic Debris

    by Griffin P. Carter, Zachary P. McKay, Mark A. Katz, Lisbeth Disla, Dasean T. Nardone-White, Derek G Southwell, Michael C. Brown, Matthias Gromeier

    Owing to pivotal roles in CNS debris clearance and homeostasis, microglia are central targets for the therapy of neurodegenerative diseases. Intricate proximity to neurons, the inherent danger of neuroimmune toxicity, and intrinsically high plasticity and adaptability, impose high hurdles on microglia modulation. Attenuated viruses are being tested extensively against CNS malignancies (i.e., cancer virotherapy); yet, aside from viral vector-mediated payload delivery, virotherapy for non-neoplastic CNS disease remains unexplored. Here we report disseminated targeting of microglia with the highly attenuated polio:rhinovirus chimera, PVSRIPO, that culminated in profound, durable microglia reprogramming. This phenotype, rooted in extended cytoplasmic viral (v)RNA replication, was non-cytopathogenic and did not yield virus progeny or dissemination. vRNA replication in microglia triggered selective interferon (IFN) regulatory factor (IRF) 3/IRF7 transcriptional programs in the relative absence of NFκB-driven proinflammatory cytokine responses and elicited robust phagocytosis of both tumor cells and amyloid-beta. Targeting of microglia with PVSRIPO mediated immunotherapy in a mouse glioma model and the clearance of oligomeric amyloid-beta deposits in an injectable model of neurotoxic amyloid accumulation. This work identifies attenuated virotherapy as an approach to safely and effectively invigorate microglia function in immune surveillance and neurotoxic debris clearance.

  • High-frequency oscillations in intraoperative recordings from hybrid arrays with micro-and macrocontacts

    by Cecilia Schmitz, Katrina J Barth, Charles Wang, Zachary Spalding, Suseendrakumar Duraivel, Birgit Frauscher, Derek Southwell, Gregory Cogan, Justin Blanco, Jonathan Viventi

    Objective: High-frequency oscillations (HFOs) are a potential biomarker of the epileptogenic zone (EZ) in patients with focal epilepsy. Previous research has estimated that HFOs arise from regions as small as a single cortical column (1 mm3), making events difficult to detect with the coarse spatial sampling of clinical-standard electrocorticographic (ECoG) arrays. We tested whether high-resolution micro-electrocorticograpic (µECoG) arrays enable improved detection of HFOs compared to clinical-scale ECoG arrays. Methods: We designed a hybrid array with both micro- (200 µm diameter, 1 mm spacing) and macrocontacts (2.3 mm diameter, 10 mm spacing). We used the arrays to record neural activity from cortical areas exposed during surgical resections for focal epilepsy (n=3 subjects). We identified HFOs in the ripple (80–250 Hz) and fast ripple (250–600 Hz) bands using a common energy thresholding criterion. We mapped HFO activity and quantified differences in event count, detection rate, amplitude, signal-to-noise ratio, and spatial extent between contact configurations. Results: Microcontacts detected 14x as many HFO events as macrocontacts while spanning the same area of cortex. The highest rates of HFO detections occurred on microcontacts positioned within the inter-contact spacing of the macrocontacts. 82% of microcontact HFOs spanned multiple contacts, providing an estimate that events typically involved a 1.25 mm radius of cortex. The remaining 18% occurred on only one 200-µm-diameter contact. In contrast, only 15% of macrocontact HFOs were large enough to span multiple contacts and were estimated to involve a 10.3 mm radius of cortex, a significantly larger region than that of microcontacts (p < 0.0001, Wilcoxon rank sum). Significance: High-resolution microcontacts captured 99% of HFOs, including 93% undetected by clinical-scale macrocontacts, revealing that most events arose from a <1 mm radius of cortex and providing further rationale for the development of µECoG arrays for EZ localization in patients with drug-resistant epilepsy.

  • Impact of antiseizure medication taper on electroencephalographic dynamics in focal epilepsy: A stereoelectroencephalographic study

    by Guoping Ren, Sana Hannan, Katharina Schiller, John Thomas, Matthew Moye, Tamir Avigdor, Kassem Jaber, Xiaoyan Wei, Hongyi Ye, Alyssa Ho, et al.

    Objective: Tapering of the antiseizure medication dosage in the epilepsy monitoring unit can provoke seizures, but its effects on seizure dynamics remain poorly characterized. This study addresses three questions: (1) Does antiseizure medication tapering influence spatiotemporal dynamics of seizures? (2) Does the tapering rate affect these dynamics? (3) Does tapering have a similar effect on interictal epileptic discharges as it does on seizures? Methods: Patients with drug‐resistant epilepsy undergoing stereoelectroencephalographic (stereo‐EEG) presurgical evaluations at Duke University Medical Center ( n = 104) and the Montreal Neurological Institute and Hospital ( n = 80) were screened. We included patients in whom the antiseizure medication dosage was tapered from the highest daily dosage (high dosage) to ≤ 50% (low dosage) during stereo‐EEG monitoring, and at least one seizure from the same focus was recorded in both conditions. Using an intrapatient design, we compared seizure onset‐zone, onset pattern, and propagation dynamics between the two conditions. Given the intrinsic seizure variability, comparisons were made between same‐dosage and cross‐dosage seizure pairs. We further assessed effects of tapering rates and examined the characteristics of interictal epileptiform discharges. Results: Among 30 patients, the proportion of channels in the seizure onset zone did not differ between high‐dosage and low‐dosage conditions (7.25% vs. 8.95%, p = .50, d = −.04). Similarly, no differences were observed in the overlap ratio of seizure‐onset regions (62% vs. 64%, p = .72, d = −.01), or the cross‐correlation of seizure‐onset patterns (.36 vs. .35, p = .54, d = .04) when comparing same‐dosage versus cross‐dosage seizure pairs. Conversely, seizures at low dosage involved more channels (40.71% vs. 81.49%, p = .001, d = −.39) and lasted longer (33.36 s vs. 74.30 s, p < .01, d = −.47). Tapering rate did not affect seizure dynamics. The mean interictal epileptiform discharge rate and number of propagation channels also remained unchanged. Significance: Despite seizure exacerbation during antiseizure medication tapering, seizure‐onset location remained stable. This supports the robustness of seizure‐based localization even under reduced medication levels and rapid tapering regimens.


  • Open Access

    Intraoperative laryngeal muscle and heart rate responses to implanted vagus nerve stimulation

    by Kathryn M. Turk, Kevin J. Mohsenian, Jennifer J. Peters, Derek G. Southwell, Warren M. Grill, Nicole A. Pelot

    1. Objectives: Implanted cervical vagus nerve stimulation (VNS) is used to treat refractory epilepsy, depression, stroke sequelae and rheumatoid arthritis. The therapeutic efficacy of VNS is limited by stimulation- induced side effects, including hoarseness, coughing, and voice alteration. We quantified VNS-evoked laryngeal muscle activation (EMG; indicating side effects) and changes in heart rate (HR; proxy for activation of therapeutic fibers) in participants undergoing VNS implant surgery. Methods: We recruited adult participants (7F/3M) with treatment-resistant epilepsy who were receiving a new VNS implant (“acute”) or replacement of an implanted VNS pulse generator (“chronic”). During these procedures, we delivered VNS across pulsewidths (50, 250, and 1000 µs/phase) and stimulation amplitudes (0.05-28 mA) while recording laryngeal EMG and HR. Results: The median stimulation amplitudes to evoke 50% of maximal laryngeal EMG response were 1.32, 0.49, and 0.34 mA for pulsewidths of 50, 250, and 1000 µs/phase, respectively; thresholds were comparable between EMG electrodes placed endotracheally and subcutaneously. The median stimulation amplitudes to cause a 10% decrease in HR were 13.39 and 3.53 mA at 50 and 250 µs/phase, respectively—i.e., ~6 to 63x higher than the 50% EMG thresholds. We did not observe a difference in EMG or HR responses between sexes, acute/chronic, or stimulation polarities. For each subject in the chronic implant group, clinician- selected stimulation amplitudes were higher than the 50% EMG thresholds and lower than the 10% HR thresholds. Conclusions: Thresholds to evoke bradycardia were ~2x higher than clinician-selected stimulation amplitudes. This indicates that the target fibers of VNS for epilepsy may be larger diameter than those projecting to the heart. Alternatively, the therapeutic effect in refractory epilepsy may be evoked with less fiber activation than is required to produce bradycardia.

  • Open Access

    Thalamo-cortical Synchrony Shapes Seizure Expression in Human Temporal Lobe Epilepsy

    by Thandar Aung, Jian Li, Tipakorn Tumnark, Chandana Belly, John Thomas, Kassem Jaber, Prachi Parikh, Muhammad Zafar, Derek Southwell, Patrick Chauvel, et al.

    In drug-resistant temporal lobe epilepsy (DR-TLE), electrographic seizures with clinical symptoms (CS) largely determine quality of life, yet some remain silent (NCS) despite arising from the same seizure-onset zone (SOZ). While surgical resection can be curative in select cases, many patients particularly those with bilateral TLE or unresectable networks are not surgical candidates. For these individuals, clarifying why some seizures produce symptoms while others do not is essential for advancing therapy. We hypothesized that thalamo-cortical network engagement may explain this divergence. 286 seizures from 62 DR-TLE patients, included coverage of the pulvinar and/or anterior thalamic group, were analyzed. Thalamo-cortical synchrony, quantified as the correlation between time–frequency patterns in thalamic nuclei and the cortical SOZ, was investigated in relation to seizure type, epilepsy subtype, thalamic region, and one-year post-resection surgical outcome. Thalamo-cortical synchrony was stronger during CS than NCS (p < 0.0001, δ > 0.6), regardless of epilepsy subtype, thalamic region, seizure subtype, or outcome, and confirmed within patients. Multivariate analysis identified seizure type as the only independent predictor (p < 0.001). These findings establish thalamo-cortical synchrony as a network-level marker of clinical seizure expression and highlight the potential of neuromodulation to modulate seizure expression when resection is not feasible.

  • Open Access

    RNA-programmable cell-type monitoring and manipulation in the human cortex with CellREADR

    by Elizabeth A. Matthews, Jeffrey B. Russ, Yongjun Qian, Shengli Zhao, Peyton Thompson, Muhib Methani, Matthew Vestal, Z. Josh Huang, Derek Southwell


  • Open Access

    RNA-programmable cell type monitoring and manipulation in the human cortex with CellREADR

    by Elizabeth A. Matthews, Jeffery B. Russ, Yongjun Qian, Shengli Zhao, Peyton Thompson, Muhib Methani, Matthew L. Vestal, Z. Josh Huang, Derek G. Southwell

    SUMMARY: Reliable and systematic access to diverse cell types is necessary for understanding the organization, function, and pathophysiology of human neural circuits. Methods for targeting human neural populations are scarce and currently center on identifying transcriptional enhancers and engineering viral capsids. Here we demonstrate the utility of CellREADR, a programmable RNA sensor-effector technology that couples cellular RNA sensing to effector protein translation, for accessing, monitoring, and manipulating specific neuron types in human cortex, ex vivo . We designed CellREADRs to target two subpopulations, CALB2 GABAergic interneurons and FOXP2 glutamatergic projection neurons, then validated targeting specificity using histological, electrophysiological, and transcriptomic methods. CellREADR expression of channelrhodopsin and GCamp enabled the manipulation and monitoring of these populations in live cortical microcircuits. By demonstrating specific, reliable, and programmable experimental access to human neuronal subpopulations, our results highlight CellREADR’s potential for studying neural circuits and treating brain disorders.